RegenCell BioScience Holdings (RGC)

[shinhari1309]

Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period.

Regencell Bioscience Holdings Limited announced the results from an analysis of a total of 51 individuals enrolled in its additional Evaluation and Assessment of RGC-COV19TMTCM through a Holistic approach efficacy trial conducted by Regencell Bioscience Asia Limited of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation).

These results are consistent with the earlier analysis announced in February 2022, showing RGC-COV19TM is effective in reducing and eliminating COVID-19 symptoms within 6 days, which in turn reduces the risk of hospitalization and death. The results have yet to be peer-reviewed.

While emerging new COVID-19 variants continue to remain a threat to the public health, Regencell will continue to work in tandem with its R&D units to develop new breakthroughs designed to transform the way COVID-19 is being managed globally and provide safe and effective treatment for everyone.